Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Reversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 synthesis and platelet aggregation. Platelet function recovers as the drug is cleared, unlike the irreversible effect of aspirin.
Indications / reported uses
Prevention of thromboembolic events in selected patients with cardiovascular or cerebrovascular disease under local product authorisation; indication and use relative to other antiplatelets are jurisdiction-specific.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Indobufen PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Indobufen Permitted Daily Exposure (PDE) report (the Indobufen PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Indobufen Occupational Exposure Limit (OEL) report (the Indobufen OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.